Wolfe Research initiated coverage of Avidity Biosciences (RNA) with an Outperform rating and $55 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Promising Developments in Avidity Biosciences’ FSHD Program Justify Buy Rating
- Avidity Biosciences initiated with a Strong Buy at Raymond James
- Avidity Biosciences Holds 2025 Annual Stockholder Meeting
- Avidity Biosciences: Promising Developments and FDA Endorsement Position for Potential Regulatory Approvals by 2027
- Avidity Biosciences price target raised to $75 from $70 at Citi